LABT (Lakewood-Amedex Biotherapeutics) Total Assets: $0.20 Mil (As of Mar. 2026)


LABT Lakewood-Amedex Biotherapeutics Inc LABT
8 GF Score
Price $3.55
View Full Analysis

What is Lakewood-Amedex Biotherapeutics Total Assets?

Lakewood-Amedex Biotherapeutics LABT +2.33% 8 Total Assets is $0.20 Mil as of Mar. 2026. GuruFocus rates LABT with a GF Score™ of 8/100.

Lakewood-Amedex Biotherapeutics's Total Assets for the quarter that ended in Mar. 2026 was $0.20 Mil.

During the past 12 months, Lakewood-Amedex Biotherapeutics's average Total Assets Growth Rate was -36.90% per year.

Total Assets is connected with ROA %. Lakewood-Amedex Biotherapeutics's annualized ROA % for the quarter that ended in Mar. 2026 was -1,089.09%. Total Assets is also linked to Revenue through Asset Turnover. Lakewood-Amedex Biotherapeutics's Asset Turnover for the quarter that ended in Mar. 2026 was 0.00.

Lakewood-Amedex Biotherapeutics  (NAS:LABT) Total Assets Explanation

Total Assets is connected with ROA %.

Lakewood-Amedex Biotherapeutics's annualized ROA % for the quarter that ended in Mar. 2026 is

ROA %=Net Income (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=-3.692/( (0.482+0.196)/ 2 )
=-3.692/0.339
=-1,089.09 %

Note: The Net Income data used here is four times the quarterly (Mar. 2026) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Lakewood-Amedex Biotherapeutics's Asset Turnover for the quarter that ended in Mar. 2026 is

Asset Turnover
=Revenue (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=0/( (0.482+0.196)/ 2 )
=0/0.339
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Lakewood-Amedex Biotherapeutics Total Assets Related Terms

Lakewood-Amedex Biotherapeutics Total Assets Historical Data

* Premium members only.

The historical data trend for Lakewood-Amedex Biotherapeutics's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lakewood-Amedex Biotherapeutics Total Assets Chart

Lakewood-Amedex Biotherapeutics Annual Data
Trend Dec23 Dec24 Dec25
Total Assets
6.89 1.07 0.48

Lakewood-Amedex Biotherapeutics Quarterly Data
Dec23 Sep24 Dec24 Mar25 Sep25 Dec25 Mar26
Total Assets Get a 7-Day Free Trial 1.07 0.00 0.99 0.48 0.20
LABT
8GF Score
Lakewood-Amedex Biotherapeutics Inc LABT
Total Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lakewood-Amedex Biotherapeutics Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Lakewood-Amedex Biotherapeutics's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as

Total Assets=Total Equity (A: Dec. 2025 )+Total Liabilities (A: Dec. 2025 )
=-1.965+2.446
=0.48

Lakewood-Amedex Biotherapeutics's Total Assets for the quarter that ended in Mar. 2026 is calculated as

Total Assets=Total Equity (Q: Mar. 2026 )+Total Liabilities (Q: Mar. 2026 )
=-2.842+3.038
=0.20

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Assets →
What does a Total Assets of $0.20 Mil mean?
Lakewood-Amedex Biotherapeutics (LABT) has a Total Assets of $0.20 Mil as of Mar. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on Lakewood-Amedex Biotherapeutics and its competitors.
Is Lakewood-Amedex Biotherapeutics' Total Assets too high?
Lakewood-Amedex Biotherapeutics' current Total Assets is $0.20 Mil. Overall, Lakewood-Amedex Biotherapeutics has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Lakewood-Amedex Biotherapeutics' Total Assets compare to CURX and PBM?
Lakewood-Amedex Biotherapeutics' Total Assets of $0.20 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Lakewood-Amedex Biotherapeutics and its competitors. Lakewood-Amedex Biotherapeutics's current Total Assets is $0.20 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lakewood-Amedex Biotherapeutics stock overvalued right now?
Lakewood-Amedex Biotherapeutics (LABT) has a current Total Assets of $0.20 Mil. The current Total Assets is $0.20 Mil. Lakewood-Amedex Biotherapeutics' overall GF Score™ is 8/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Lakewood-Amedex Biotherapeutics (LABT), the current Total Assets is $0.20 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Lakewood-Amedex Biotherapeutics Business Description

Address 8031 Cooper Creek Blvd, Unit 103, University Park, FL, USA, 34201
Lakewood-Amedex Biotherapeutics Inc is a clinical-stage biotechnology company developing a novel class of fast-acting, broad-spectrum antimicrobials - the Bisphosphocin class - to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. The company's main product is Nu-3, a topically delivered antimicrobial gel in Phase 2 clinical trials for the treatment of mildly infected diabetic foot ulcers (iDFU). It is also advancing a portfolio of early-stage pipeline compounds developed from its Bisphosphocin platform targeting potential disease indications, including complicated urinary tract infection (cUTI) and pulmonary infections.
8GF Score

Get the complete analysis for LABT

Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.55
Price